Hypermed, Inc.
HyperMed Imaging, Inc. is a privately owned medical device company based in Memphis, TN, and a market leader in hyperspectral medical imaging for surface tissue oximetry. Since 2006, it has pioneered technology to assess oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue, with applications in wound care, vascular, and reconstructive surgery. The company's flagship product, HyperView™, is FDA 510(k) cleared and offers non-invasive, portable tissue oxygenation assessment to improve clinical outcomes and support tissue viability.
Industries
Nr. of Employees
small (1-50)
Patents
Systems and methods for performing an imaging test under constrained conditions
US-11399716-B2
View DetailsHyperspectral technology for assessing and treating diabetic foot and tissue disease
US-10028676-B2
View Details
Systems and methods for performing an imaging test under constrained conditions
US-11399716-B2
View DetailsHyperspectral technology for assessing and treating diabetic foot and tissue disease
US-10028676-B2
View DetailsProducts
Handheld hyperspectral tissue oximetry imaging device
A handheld, battery-operated, portable diagnostic imaging device that performs non-contact measurement of superficial tissue oxygenation and produces two-dimensional color-coded maps reporting approximate oxygen saturation, oxyhemoglobin and deoxyhemoglobin levels for selected skin regions.
Handheld hyperspectral tissue oximetry imaging device
A handheld, battery-operated, portable diagnostic imaging device that performs non-contact measurement of superficial tissue oxygenation and produces two-dimensional color-coded maps reporting approximate oxygen saturation, oxyhemoglobin and deoxyhemoglobin levels for selected skin regions.
Services
Collaborative clinical testing and validation of hyperspectral tissue oximetry technology to generate clinical evidence for diagnostic use in wound care, vascular compromise and reconstructive surgery.
Collaborative clinical testing and validation of hyperspectral tissue oximetry technology to generate clinical evidence for diagnostic use in wound care, vascular compromise and reconstructive surgery.
Expertise Areas
- Surface tissue oximetry
- Hyperspectral optical imaging (visible light)
- Clinical validation and trial support
- Regulatory compliance and certification (FDA 510(k), CE, UL)
Key Technologies
- Visible-light hyperspectral imaging
- Optical spectrometer-based oximetry
- Non-contact optical oximetry
- 2D color-coded oxygenation mapping
News & Updates
April 2, 2018 / Memphis, TN. HyperMed received approval to apply the CE Mark for HyperView™, allowing distribution in Europe. HyperView is a fast, handheld, non-invasive, portable device for assessing tissue oxygenation, providing data on oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue. It aims to assist clinicians in wound healing and vascular assessment.
January 10, 2017 / Memphis, TN. HyperMed announced FDA clearance for HyperView™, a handheld, battery operated, non-contact tissue oxygenation device. It provides hyperspectral images and data for superficial tissue oxygenation, aiding in the assessment of circulatory compromise.
February 1, 2015 / Memphis, TN. The company moved its headquarters from Greenwich, CT to Memphis, TN, citing improved operational costs and access to qualified medical device talent. The company continues to develop its next-generation hyperspectral imaging devices.
January 1, 2014 / Greenwich, CT. HyperMed completed its first private Series B financing to fund development, testing, clinical trials, and regulatory activities for its new tissue oximetry device. The company has over 30 patents issued and more than 40 pending.
January 1, 2012 / Greenwich, CT. Mark Darty was hired as CEO. He has extensive experience in medical devices and technology commercialization, with a background in leading companies through growth and acquisition.
April 2, 2018 / Memphis, TN. HyperMed received approval to apply the CE Mark for HyperView™, allowing distribution in Europe. HyperView is a fast, handheld, non-invasive, portable device for assessing tissue oxygenation, providing data on oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue. It aims to assist clinicians in wound healing and vascular assessment.
January 10, 2017 / Memphis, TN. HyperMed announced FDA clearance for HyperView™, a handheld, battery operated, non-contact tissue oxygenation device. It provides hyperspectral images and data for superficial tissue oxygenation, aiding in the assessment of circulatory compromise.
February 1, 2015 / Memphis, TN. The company moved its headquarters from Greenwich, CT to Memphis, TN, citing improved operational costs and access to qualified medical device talent. The company continues to develop its next-generation hyperspectral imaging devices.
January 1, 2014 / Greenwich, CT. HyperMed completed its first private Series B financing to fund development, testing, clinical trials, and regulatory activities for its new tissue oximetry device. The company has over 30 patents issued and more than 40 pending.
January 1, 2012 / Greenwich, CT. Mark Darty was hired as CEO. He has extensive experience in medical devices and technology commercialization, with a background in leading companies through growth and acquisition.